Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check5 days agoChange DetectedThe page's footer revision was updated from v3.6.5 to v3.6.6, representing a maintenance/template update. It does not change the study content or how users interact with the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a new release of the page template. This is a technical update with no indicated changes to study details or visible content.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page revision changed from v3.6.3 to v3.6.4, reflecting a minor backend/update with no visible changes to study content or layout.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page now displays a new site revision label, Revision: v3.6.3, replacing the previous Revision: v3.6.0. This indicates a software update to the site rather than changes to the clinical study information shown on the page.SummaryDifference0.1%

- Check83 days agoChange DetectedThe investigators section was updated to include Hiroaki Akamatsu and adjust institution references. New help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment label formatting was updated, and the revision tag changed from v3.5.5 to v3.6.0.SummaryDifference2%

- Check90 days agoChange DetectedThe page now shows Revision: v3.5.5, indicating a new site revision. This replaces the previous Revision: v3.5.4 and reflects a minor platform update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.